The 21-Gene Recurrence Score Assay (Oncotype DX™) in Estrogen Receptor-Positive Male Breast Cancer: Experience in an Israeli Cohort

Publisher： Karger

E-ISSN： 1423-0232|87|1|1-6

ISSN： 0030-2414

Source： Oncology, Vol.87, Iss.1, 2014-06, pp. : 1-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Preoperative Neutrophil/Lymphocyte Ratio Does not Correlate with the 21-Gene Recurrence Score in Estrogen Receptor-Positive Breast Cancer Patients

By  

Oncology Research and Treatment, Vol. 38, Iss. 1-2, 2015-01 ,pp. : 24-27

Karger

Access to resources Recommend Favorite

Apparent diffusion coefficient in estrogen receptor‐positive and lymph node‐negative invasive breast cancers at 3.0T DW‐MRI: A potential predictor for an oncotype Dx test recurrence score

By  

JOURNAL OF MAGNETIC RESONANCE IMAGING, Vol. 47, Iss. 2, 2018-02 ,pp. : 401-409

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of the Onco type DX™ 21-Gene Assay to Guide Adjuvant Decision Making in Early-Stage Breast Cancer

By Conlin Alison K.   Seidman Andrew D.  

Molecular Diagnosis & Therapy, Vol. 11, Iss. 6, 2007-01 ,pp. : 355-360

Adis International

Access to resources Recommend Favorite

Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cells: Regulation of Expression of Cancer-Related Genes by Estradiol and Tamoxifen

By  

Current Signal Transduction Therapy, Vol. 3, Iss. 1, 2008-01 ,pp. : 7-21

Bentham Science Publishers

Access to resources Recommend Favorite

The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor‐positive breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 3, 2015-08 ,pp. : 686-697

John Wiley & Sons Inc

Access to resources Recommend Favorite